N-Methyl-3,4-methylenedioxyamphetamine
"N-Methyl-3,4-methylenedioxyamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
Below are MeSH descriptors whose meaning is more general than "N-Methyl-3,4-methylenedioxyamphetamine".
Below are MeSH descriptors whose meaning is more specific than "N-Methyl-3,4-methylenedioxyamphetamine".
This graph shows the total number of publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in Harvard Catalyst Profiles by year, and whether "N-Methyl-3,4-methylenedioxyamphetamine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 1 | 4 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 2 | 0 | 2 |
Below are the most recent publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in Profiles.
-
Older adults in psychedelic-assisted therapy trials: A systematic review. J Psychopharmacol. 2024 Jan; 38(1):33-48.
-
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Curr Neuropharmacol. 2024; 22(4):636-735.
-
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results. Neurosci Biobehav Rev. 2023 Nov; 154:105421.
-
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. 2023 07; 11(7):454-464.
-
Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022 08 15; 439:120302.
-
Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys. Int J Neuropsychopharmacol. 2021 08 20; 24(8):656-665.
-
Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses. Pharmacol Biochem Behav. 2021 03; 202:173112.
-
Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting. J Nerv Ment Dis. 2016 Jul; 204(7):519-23.
-
Letter in response to "MDMA-induced angioedema treated with icatibant". Clin Toxicol (Phila). 2016 Mar; 54(3):293.
-
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015 Sep 15; 5:e634.